How Lipitor Binds to Proteins in the Body
Lipitor (atorvastatin) primarily interacts with HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. It binds competitively to the enzyme's active site as a substrate analog, mimicking HMG-CoA and inhibiting its activity to reduce liver cholesterol production.[1]
Key Protein Binding in Blood Plasma
Over 98% of Lipitor circulates bound to plasma proteins, mainly albumin (about 70-80%) and alpha-1-acid glycoprotein (15-20%). This high binding limits free drug availability for tissues while aiding distribution.[1][2]
Role of Cytochrome P450 Proteins in Metabolism
Lipitor undergoes hepatic metabolism via CYP3A4 and CYP2C9 enzymes. It acts as a substrate for these proteins, forming active metabolites like 2-hydroxyatorvastatin, which contribute to cholesterol-lowering effects. CYP3A4 handles most oxidative metabolism.[1][3]
Interactions with Drug Transporter Proteins
Lipitor is a substrate for hepatic uptake transporters OATP1B1 and OATP1B3, facilitating liver entry for metabolism. It also interacts with efflux proteins like P-glycoprotein (P-gp) and BCRP, affecting intestinal absorption and biliary excretion.[2][3]
Clinical Implications of Protein Interactions
High plasma protein binding raises displacement risks with drugs like warfarin or fibrates, potentially increasing free Lipitor levels and toxicity (e.g., myopathy). CYP3A4 inhibitors (e.g., itraconazole) slow metabolism, elevating exposure; inducers (e.g., rifampin) reduce efficacy.[1][2]
Sources
[1]: Lipitor Prescribing Information (FDA)
[2]: DrugBank: Atorvastatin
[3]: PharmGKB: Atorvastatin Pathway